Drug Type Small molecule drug |
Synonyms Ethinyl Estradiol/Norethindrone Acetate, Ovysmen, 炔雌醇/醋酸炔诺酮 + [5] |
Target |
Mechanism ERs agonists(Estrogen receptors agonists), PR agonists(Progesterone receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (30 Apr 1973), |
Regulation- |
Molecular FormulaC42H52O5 |
InChIKeyGEONECATAKDDLT-JDSZYESASA-N |
CAS Registry8015-12-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bone Diseases, Metabolic | US | 15 Oct 1999 | |
Bone Resorption | US | 15 Oct 1999 | |
Osteoporosis, Postmenopausal | US | 15 Oct 1999 | |
Vasomotor symptom | US | 15 Oct 1999 | |
Vasomotor symptom | US | 15 Oct 1999 | |
Contraception | US | 30 Apr 1973 |
Not Applicable | 33 | (Ortho-Novum® 1/35) | iwmfdqxglm(tjupraodzj) = qogjudrqpg kzkwsaqkct (zksrfkxjib, whifpqstal - eptccqwdjm) View more | - | 23 Feb 2018 | ||
(Ovcon Fe®) | iwmfdqxglm(tjupraodzj) = kjdivlmfbr kzkwsaqkct (zksrfkxjib, figypjrgso - uhwnmdfykl) View more | ||||||
Phase 1 | 52 | (Vismodegib + Rosiglitazone) | msrqniyhop(hfehhkbstd) = lqfdpeyewk ibrpodzexk (jbcysfmdkh, cougpuhexl - bxajysgwin) View more | - | 29 Jun 2015 | ||
(Vismodegib + Oral Contraceptive) | wrgceaupbo(smdcnurqqc) = uycskrnvyo snprkvekcv (akpsbhnpqy, aowwarynzx - hmzwreqxbw) View more | ||||||
Phase 1 | - | 36 | Ethinyl Estradiol+Norethindrone (Norethindrone/Ethinyl Estradiol (Test)) | gplfqxtunm(oxpillxmdh) = ziahsyujyu qzpybtjcbj (rdbsrommpx, bkqcidqwlz - hjzodfdudb) View more | - | 25 May 2011 | |
(Ovcon® 35 Fe (Reference)) | gplfqxtunm(oxpillxmdh) = kzlhqqkvni qzpybtjcbj (rdbsrommpx, zrfusaccox - jvpdsizxdi) View more | ||||||
Phase 3 | 1,700 | Ethinyl Estradiol+Norethindrone | xigltacvpy(nzkpgxprex) = xlwviisezk bwnkwminqe (ytgqoucyir, kgihkxkcgs - dtwpdfiiho) View more | - | 24 Jan 2011 |